Other
Dec 2022Commercialization depends on FDA clearance for broader hospital/lab sales; public filings describe pre-commercial, research-use-only sales and regulatory execution risk.
SourceBlood testing device for early diagnosis of cancer and treatment…
Company research
Public company, workplace, funding, and market signals
Overview
Delee is a medtech/biotech startup focused on liquid-biopsy cancer diagnostics and treatment monitoring through circulating tumor cell (CTC) isolation and analysis.
Primary product
CytoCatch™ Isolation Platform and Imaging System
Founded
2017
Headquarters
1211 San Dario Avenue, Laredo, TX 78040, United States
Team size
11
Industry
Biotechnology Research
Sub-industry
Medical devices / cancer diagnostics
Offices
Laredo, Texas, United States
Monterrey, Mexico
California, United States
Business model
razor-and-blades platform + consumables
B2B sales to research centers, pharma, hospitals, and labs
research-use-only sales before FDA clearance
Funding
Stage
Seed / equity crowdfunding
Total raised
$2.6M
Latest round
Equity Crowdfunding (Reg CF) · Dec 2022
Latest amount
$204.1K
People & investors
Leadership
Co-Founder and Strategist; former CEO
Co-Founder, CMO, and Director
Co-Founder, CTO, and former Director of Engineering
Joost Leeflang
Director
Work & culture
Public sources describe a multidisciplinary team of scientists, engineers, and advisors focused on automation, clinical validation, and lower-cost cancer testing.
Product & market
Pricing
Razor-and-blades model: platform sales plus recurring reagents and consumables; initially sold as a research-use-only device, then as a diagnostic medical device after FDA clearance.
Differentiators
- —isolates CTCs regardless of membrane protein expression
- —fully automated sample-processing and imaging workflow
- —single-CTC sensitivity against a very large blood-cell background
- —machine-vision / ML-based cell classification
- —compatible with downstream molecular biology techniques
- —designed to support early detection and therapy monitoring at lower cost
Technology
Branch
Google Analytics
Google Maps
Cloudflare Browser Insights
New Relic
machine learning
microfluidics
automated fluorescence microscopy
Customers
research centers
pharmaceutical companies
universities
cancer research centers
hospitals
laboratories
Competitors
CellSearch System (Menarini & Silicon Biosystems)
Angle plc
Epic Biosciences
Apocell
RareCyte
Scale & contact
Estimated revenue
About $2.3M ARR (GetLatka, 2025); some secondary profiles list $1M-$10M
Estimated monthly visits
1.7K
Traffic estimate as of Jul 2026
Signals & risks
Latest news
The Ganesha Lab · Jan 2024
Profiles Delee’s participation in RESI JP Morgan 2024 after winning the BIGinBIO Excellence Award, and quotes Juan Felipe Yee on investor meetings and progress on the business model.
The Ganesha Lab · Jan 2023
Notes that Delee was one of the fund’s inaugural investments and describes the company as a Mexican startup working on liquid-biopsy-based early cancer diagnostics.
Forbes · Jul 2020
Early profile of Liza Velarde and Delee’s CytoCatch device, including the company’s fundraising story and early commercialization goals.
LinkedIn · Jan 2020
Company update announcing a Republic crowdfunding milestone and thanking supporters; useful as a contemporaneous fundraising signal.
Scientific Reports · Sep 2019
Peer-reviewed research tied to Delee’s team describing a fully automated microscope for CTC imaging and classification.
Jobs and careers at Delee
0 jobs at Delee
No open positions
Check back later for new openings